PCVX
Vaxcyte, Inc.Company Information
- Company Name
- Vaxcyte, Inc.
- CIK
- CIK0001649094
- Category
- Large accelerated filer
- Ticker: Exchange
- PCVX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- PCVX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-09
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 160,110
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 152,688,384
- Shares outstanding
- 144,494,106
- Ownership
- 105.67%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- 7.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 183 | 261 | 174 | 281 | 307 | 347 | 388 | 1,050 | 519 | 612 | 397 | 545 | ||||||
| Short Term Investments | 1,304 | 1,476 | 1,387 | 1,430 | 1,355 | 1,325 | 1,359 | 1,130 | 934 | 875 | 683 | 721 | ||||||
| Prepaid Expense And Other Assets Current | 66 | 76 | 66 | 56 | 54 | 45 | 41 | 33 | 29 | 31 | 16 | 30 | ||||||
| Assets Current | 1,553 | 1,813 | 1,627 | 1,767 | 1,716 | 1,717 | 1,788 | 2,214 | 1,481 | 1,517 | 1,096 | 1,295 | ||||||
| Property Plant And Equipment Net | 260 | 261 | 257 | 253 | 242 | 217 | 198 | 163 | 126 | 85 | 80 | 11 | ||||||
| Operating Lease Right Of Use Asset | 110 | 113 | 116 | 84 | 86 | 88 | 72 | 29 | 27 | 29 | 31 | 16 | ||||||
| Long Term Investments | 1,021 | 1,004 | 882 | 959 | 1,165 | 1,279 | 1,388 | 1,093 | 399 | 413 | 163 | 169 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 193 | 156 | 119 | 107 | 95 | 76 | 64 | 60 | 53 | 46 | 38 | 3 | ||||||
| Assets Noncurrent | 1,585 | 1,535 | 1,375 | 1,404 | 1,590 | 1,662 | 1,723 | 1,346 | 606 | 574 | 312 | 201 | ||||||
| Assets | 3,138 | 3,348 | 3,003 | 3,172 | 3,305 | 3,378 | 3,511 | 3,560 | 2,087 | 2,091 | 1,408 | 1,496 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 101 | 63 | 71 | 49 | 31 | 21 | 48 | 18 | 10 | 22 | 15 | 16 | ||||||
| Employee Related Liabilities Current | 14 | 8 | 23 | 17 | 11 | 6 | 21 | 12 | 6 | 3 | 11 | 7 | ||||||
| Accrued Liabilities Current | 25 | 30 | 31 | 25 | 32 | 26 | 29 | 31 | 22 | 54 | 60 | 15 | ||||||
| Operating Lease Liability Current | 7 | 6 | 6 | 6 | 6 | 6 | 6 | 10 | 7 | 7 | 7 | 6 | ||||||
| Liabilities Current | 271 | 242 | 206 | 200 | 154 | 97 | 140 | 124 | 83 | 87 | 145 | 86 | ||||||
| Operating Lease Liability Noncurrent | 109 | 110 | 111 | 79 | 80 | 81 | 65 | 18 | 18 | 20 | 22 | 8 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | - | - | - | 0 | - | - | - | 0 | 0 | ||||||
| Liabilities | 380 | 352 | 317 | 279 | 234 | 178 | 205 | 142 | 101 | 107 | 167 | 93 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 5,525 | 5,478 | 4,839 | 4,800 | 4,769 | 4,729 | 4,698 | 4,669 | 3,132 | 3,000 | 2,165 | 2,148 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -8 | -7 | 2 | 1 | -2 | -0 | -4 | 0 | 2 | 3 | 0 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -2,760 | -2,476 | -2,155 | -1,908 | -1,696 | -1,529 | -1,388 | -1,251 | -1,148 | -1,019 | -924 | -744 | ||||||
| Stockholders Equity | 2,758 | 2,996 | 2,686 | 2,893 | 3,071 | 3,200 | 3,306 | 3,418 | 1,986 | 1,984 | 1,240 | 1,403 | ||||||
| Liabilities And Stockholders Equity | 3,138 | 3,348 | 3,003 | 3,172 | 3,305 | 3,378 | 3,511 | 3,560 | 2,087 | 2,091 | 1,408 | 1,496 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 145 | 144 | 131 | 130 | 130 | 129 | 125 | 124 | 111 | 109 | 95 | 95 | ||||||
| Shares Outstanding | 145 | 144 | 131 | 130 | 130 | 129 | 125 | 124 | 111 | 109 | 95 | 95 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVaxcyte, Inc. (PCVX) — SEC Financial Statements & Analysis
Vaxcyte, Inc. (PCVX) is a biological products, (no diagnostic substances) company, incorporated in DE. Vaxcyte, Inc. trades on Nasdaq as: PCVX. Vaxcyte, Inc. (PCVX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Vaxcyte, Inc. carries a market cap of $8.40B, a P/E ratio of -7.89x, a P/B ratio of 3.05x, an enterprise value of $8.21B, and an EV/EBITDA multiple of -7.15x. On profitability, it posts a Return on Equity (ROE) of -36.51%, a Return on Assets (ROA) of -33.03%, and a Return on Invested Capital (ROIC) of -43.67%. Per share, it reports EPS of $-7.37, diluted EPS of $-7.37, free cash flow per share of $-6.19, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 94.39% year-over-year and EPS growth of 83.01% year-over-year. On the balance sheet, it maintains a current ratio of 5.72x, a quick ratio of 5.48x, working capital of $1.28B, a debt-to-equity ratio of 0.14x, a debt ratio of 0.12, free cash flow of $-894.14M (TTM), and net debt of $-184.66M. Figures sourced from SEC EDGAR.
- Market Cap
- $8.40B
- P/E TTM
- -7.89x
- EPS TTM
- $-7.37
- P/B TTM
- 3.05x
- ROE TTM
- -36.51%
- ROA TTM
- -33.03%
- Debt To Equity
- 0.14x
- Free Cash Flow TTM
- $-894.14M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Vaxcyte, Inc. in?
Vaxcyte, Inc. (PCVX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does PCVX trade on?
Vaxcyte, Inc. (PCVX) trades on the Nasdaq.
Where is Vaxcyte, Inc. incorporated?
Vaxcyte, Inc. is incorporated in DE.
When was Vaxcyte, Inc. (PCVX)'s most recent SEC filing?
Vaxcyte, Inc. (PCVX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is PCVX's market cap?
Vaxcyte, Inc. (PCVX) has a market capitalization of $8.40B as of 2026-06-30.
What is PCVX's EPS (earnings per share)?
Vaxcyte, Inc. (PCVX)'s trailing twelve month EPS is $-7.37 as of 2026-06-30.
What is PCVX's ROE (return on equity)?
Vaxcyte, Inc. (PCVX)'s trailing twelve month Return on Equity (ROE) is -36.51% as of 2026-06-30.
What is PCVX's ROA (return on assets)?
Vaxcyte, Inc. (PCVX)'s trailing twelve month Return on Assets (ROA) is -33.03% as of 2026-06-30.
What is PCVX's ROIC (return on invested capital)?
Vaxcyte, Inc. (PCVX)'s trailing twelve month Return on Invested Capital (ROIC) is -43.67% as of 2026-06-30.
What is PCVX's EV/EBITDA?
Vaxcyte, Inc. (PCVX)'s trailing twelve month EV/EBITDA is -7.15x as of 2026-06-30.